- XIAP (X‑linked Inhibitor of Apoptosis Protein) is the most potent endogenous inhibitor of caspases in mammalian cells and a key regulator of programmed cell death. As a core member of the IAP family, XIAP prevents premature apoptosis by directly binding and suppressing caspase‑3, caspase‑7 and caspase‑9. This direct inhibition distinguishes XIAP from other IAPs such as cIAP1 and cIAP2, which primarily regulate apoptosis indirectly through ubiquitination of signalling proteins rather than through caspase binding.
- XIAP contains three BIR (Baculovirus IAP Repeat) domains and a C‑terminal RING finger ubiquitin ligase domain. The BIR2 domain binds caspase‑3 and caspase‑7, blocking their ability to cleave essential cellular substrates during apoptosis. The BIR3 domain binds caspase‑9, preventing apoptosome‑mediated activation of the intrinsic apoptotic pathway. Through these interactions, XIAP acts as a molecular brake that ensures apoptosis proceeds only under appropriate physiological conditions.
- The RING domain of XIAP adds an additional layer of regulation by functioning as an E3 ubiquitin ligase. XIAP can ubiquitinate caspases, signalling proteins and components of inflammatory pathways, influencing their stability and activity. This ubiquitination allows XIAP to participate in NF‑κB signalling and modulate immune responses, linking apoptosis regulation to broader cellular signalling networks.
- XIAP activity is tightly controlled by mitochondrial proteins released during apoptosis. The most important of these is Smac/DIABLO, which binds XIAP through its IAP‑binding motif and displaces caspases from XIAP’s BIR domains. This neutralisation of XIAP allows apoptosis to proceed efficiently once mitochondrial outer membrane permeabilisation occurs. Smac mimetics—small molecules that mimic Smac/DIABLO—have been developed as anticancer therapeutics to overcome XIAP‑mediated resistance to apoptosis and restore cell death sensitivity in tumour cells.
- Beyond apoptosis, XIAP plays important roles in immune signalling. It contributes to NOD2‑mediated NF‑κB activation and regulates inflammatory pathways through ubiquitination of RIPK2. Mutations in XIAP cause X‑linked lymphoproliferative syndrome type 2 (XLP‑2), a disorder characterised by immune dysregulation, susceptibility to viral infections and defective control of inflammation. These clinical manifestations highlight XIAP’s importance beyond cell death regulation.
- XIAP is frequently overexpressed in cancer, where it promotes tumour cell survival, resistance to chemotherapy and evasion of immune‑mediated killing. Because XIAP directly inhibits caspases, its suppression can dramatically increase the sensitivity of cancer cells to pro‑apoptotic stimuli. This makes XIAP a major therapeutic target in oncology, with ongoing research exploring Smac mimetics, RNA‑based therapies and XIAP‑specific inhibitors.
- In summary, XIAP is the most powerful caspase inhibitor in mammalian cells and a central regulator of apoptosis, ubiquitination and immune signalling. Its BIR domains block caspase‑3, caspase‑7 and caspase‑9, while its RING domain modulates signalling pathways through ubiquitination. XIAP’s roles in cancer, inflammation and immune disorders make it a key focus in molecular biology and therapeutic development.
